T spot TB test.jpg


Location data
Loading map...
Medical equipment data
Health topic Tuberculosis
Health classification Diagnosis
Project data
Status Commercialized
Download Open Know How Manifest
Page data
Part of Global Health Medical Device Compendium
Type Medical equipment, Project
SDG Sustainable Development Goals SDG03 Good health and well-being
SDG09 Industry innovation and infrastructure
Authors Eva Shiu
Published 2012
License CC-BY-SA-3.0
Language English (en)
Impact Number of views to this page. Views by admins and bots are not counted. Multiple views during the same session are counted as one. 308

Problem being addressed[edit | edit source]

TB kills an estimated 2-3 million people per year worldwide, with an estimated 50% of cases going undiagnosed. Unfortunately, the TB skin test, which has been used for the past century, is prone to false negatives and false positives, particularly in developing country settings. In developing countries, a more specific and sensitive test is needed.

Detailed description of the solution[edit | edit source]

The T-SPOT TB test measures the specific antigens that stimulate the effector T cells. Effector T cells are short-lived, and their presence indicates that the cellular immune response is currently countering pathogens, and is diagnostic of an active infection. The proteins that the T-SPOT TB test measures are not found in the BCG vaccine, which eliminates one potential source for false positive rates. Additionally, these antigens are produced even by immunocompromised individuals, reducing false negative rates. The manufacturer reports that the sensitivity of the T-SPOT.TB test is 95.6% and the specificity of the T-SPOT.TB test is 97.1%.

Designed by[edit | edit source]

  • Designed: Oxford Immunotec. Main website here.
  • Manufacturing: Oxford, England.

When and where it was tested/implemented[edit | edit source]

This device has been used in different parts of the world.

Funding Source[edit | edit source]

Initial research funded and conducted through the University of Oxford. This project has also received private funding from international investors such as Clarus Ventures, Wellington Partners and DFJ Esprit. The complete list can be found here.

References[edit | edit source]

Peer-reviewed publication[edit | edit source]

Dozens of peer-reviewed publications are provided by Oxford Immunotec in the following list.

Oxford Immunotec. Cost-Effectiveness Studies. Retrieved in 2010. Link available here.

  • NOTE: There are over 1500 papers that reference this technology online in Google Scholar with the search term "T-spot TB."

Other internally generated reports[edit | edit source]

Guidelines for use for multiple countries. Link available here.

Press releases. Link available here.

IP and copyright[edit | edit source]

IP and copyrights are privately held by Oxford Immunotech.

Approval by regulatory bodies or standards boards[edit | edit source]

FDA approval in US (30 July 2008) Carries CE mark in EU as of 2004. Approved in Canada in 2005. Approval currently being sought in other countries.

Share your opinion